Abstract
In 1957 a substance was described (Isaacs and Lindenmann 1957) which was produced by virus-infected cell cultures and “interfered” with infection by other viruses; it was called interferon. Over the following decades it was realized that “interferon” comprises a family of related proteins with several additional properties. Starting in the 1960s various “factors” produced primarily by white blood cell (WBC) as well as other cell supernatants were described which acted in various ways on other WBCs or somatic cells. They were usually given a descriptive name either associated with their cell of origin or their activity on other cells resulting in a myriad of names. The application of molecular technology allowed us to determine that some cytokines had multiple activities and that different cytokines had similar overlapping activities. A systematic classification based on genetic structure and protein characterization has been effective. The interactive networks and cascades of cytokines, interferons (IFN), interleukins (IL), growth factors (GF), chemokines (CK), their receptors (r or R), and signaling pathways are highly complex and will be further explored in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggarwal S, Ghilardi N, Xie M-H et al (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterised by the production of IL-17. J Biol Chem 278:1910–1914
Algranati NE, Sy S, Modi M (1999) A branched methoxy 40-kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C. Hepatology 40 (Suppl): 190A
Artillo S, Pastore G, Alberti A et al (1998) Double-blind, randomized controlled trial of interleukin-2 for the treatment of chronic hepatitis B. J Med Virol 54:167–172
Asadullah K, Sabat R, Friederich M et al (2004) Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 3:185–192
Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, Nakajima H, Karow M, Takeuchi T (2010) Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis 16(6):1017–1028
Baker DP, Lin EY, Lin K et al (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 17:179–188
Barry J, Kirby B (2004) Novel biologic therapies for psoriasis. Expert Opin Biol Ther 4:975–987
Baud’huin M, Renault R, Charrier C et al (2010) Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol 221:77–86
Biedermann T, Lametschwandtner G, Tangemann K et al (2006) IL-12 instructs skin homing of human Th2 cells. J Immunol 177:3763–3770
Bilsborough J, Leung DYM, Maurer M et al (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117:418–425
Cao SG, Zhao QY, Ding ZT et al (1990) Chemical modification of enzyme molecules to improve their characteristics. Ann N Y Acad Sci 613:460–467
Carreño V, Tapia L, Ryff JC et al (1992) Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J Med Virol 37:215–219
Carreño V, Zeuzem S, Hopf U et al (2000) A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 32:317–324
Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, Armstrong ME, Garlanda C, Mantovani A, O’Neill LA, Mills KH, Lynch MA (2008) IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem 105(5):1960–1969
Cruikshank WW, Little F (2008) Interleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 28(6):467–483
Dent P, Yacoub A, Hamed HA et al (2010) The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 128(2):375–384
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory disease. Blood 117(14):3720–3732
Doherty DH, Rosendahl MS, Smith DJ et al (2005) Site-specific PEGylation of engineered cysteine analogs of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug Chem 16:1291–1298
Donnelly RP, Kotenko SV (2010) Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30(8):555–564
Donnelly RP, Sheikh F, Dickensheets H, Savan R, Young HA, Walter MR (2010) Interleukin-26: an IL-10-related cytokine produced by th17 cells. Cytokine Growth Factor Rev 21(5):393–401
Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897–3908
El Bassam S, Pinsonneault S, Kornfeld H et al (2005) Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 117:89–96
ExPASy (2012) http://au.expasy.org/uniprot/Q9UBH0 - (Expert Protein Analysis System) proteomics server of the Swiss Institute of Bioinformatics (SIB)
Ferland R, Mulani D, Campbell PK (2001) Evaluation of a sprayable polyethylene glycol adhesion barrier in a porcine efficacy model. Human Reproduction 16(12):2718–2723
Fève B, Bastard JP (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5(6):305–311
Fort MM, Cheung J, Yen D et al (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15:985–995
Fry TJ, Mackall CL (2002) Interleukin-7: from bench to clinic. Blood 99:3892–3904
Gilmour J, Lavender P (2008) Control of IL-4 expression in T-helper 1 and 2 cells. Immunology 124:437–444
Glue P, Fang JWS, Rouzier-Panis R et al (2000) Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567
Greenfeder S, Umland SP, Cuss FM et al (2001) Th2 cytokines and asthma: the role of interleukin-5 in allergic eosinophilic disease. Respir Res 2:71–79
Guzeloglu-Kayisli O, Kayisli UA, Taylor HS (2009) The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med 27(1):62–79
Henney JM (2000) Surgical sealant for lung cancer. JAMA 284:685
HGNC (2012) - www.gene.ucl.ac.uk/nomenclature/ - Gene Families and Grouping – Interferons (IFN) – Interleukins and interleukin receptor genes (IL)
Holtsberg FW, Ensor CM, Steiner MR et al (2002) Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 80:259–271
Hu Y, Shen F, Crellin NK, Ouyang W (2011) The IL-17 pathway as a major therapeutic target in autoimmune disease. Ann N Y Acad Sci 2010(1217):60–76
Huising MO, Cruiswijck CP, Flik G (2006) Phylogeny and evolution of class-I helical cytokines. J Endocrinol 189:1–25
Hukshorn CJ, Saris WHM, Westerterp-Plantenga MS et al (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 85:4003–4009
In’t VP (2011) Insulitis in human type 1 diabetes. Islets 3(4):131–138
Isaacs A, Lindenmann J (1957) Virus interference I: the interferon. Proc R Soc Ser B 147:258–267
Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1–38
Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3345
Kim S-H, Han S-Y, Azam T et al (2005) Interleukin 32: a cytokine and inducer of TNFα. Immunity 22:131–142
Kotenko SV, Izotova LS, Mirochnitchenko OV et al (2001a) Identification of the functional IL-TIF (IL-22) receptor complex: the IL-10R2 chain (IL-10Rβ) is a common chain of both IL-10 and IL-TIF (IL-22) receptor complexes. J Biol Chem 276:2725–2732
Kotenko SV, Izotova LS, Mirochnitchenko OV et al (2001b) Identification, cloning and characterization of a novel soluble receptor which binds IL-22, and neutralizes its activity. J Immunol 166:7096–7103
Kristiansen OF, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad or the indifferent. Diabetes 54(Suppl 2):S114–S124
Kurschner C, Yuzaki M (1999) Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J Neurosci 19:7770–7780
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100:3457–3469
LaFleur DW, Nardelli B, Tsareva T et al (2001) Interferon-κ, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276:39765–39771
Larousserie F, Charlot P, Bardel E et al (2006) Differential effects of IL-27 on human B cell subsets. J Immunol 176(10):5890–5897
Lee S, Kaneko H, Sekigawa I et al (1998) Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 37:1334–1337
Leonard P, Sur S (2003) Interleukin-12: potential role in asthma therapy. BioDrugs 17:1–7
Liao W, Lin JX, Leonard WJ (2011) IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 23(5):598–604
Lin H, Lee E, Hestir K et al (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320(5877):807–811
Liu B, Nivick D, Kim SH, Rubinstein M (2000) Production of a biologically active human interleukin 18 requires its prior synthesis as PRO-IL-18. Cytokine 12(10):1519–1525
Ludwig CU, Ludwig-Habemann R, Obrist R et al (1990) Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion. Onkologie 13:117–122
Lutfalla G, Crollius HR, Stange-Thomman N et al (2003) Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: the class II cytokine receptors and their ligands in mammals and fish. BMC Genomics 4:29–44
Lyman GH (2005) Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 5:1635–1646
Malek TR, Castro I (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33(2):153–165
Marrakchi S, Guigue P, Renshaw BL et al (2011) Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620–628
Martinez-Moczygemba M, Huston DP (2003) Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunology 112(4):653–665
McLaren JE, Michael DR, Salter RC, Ashlin TJ, Calter CJ, Miller AM, Liew FY, Ramji DP (2010) IL-33 reduces macrophage foam cell formation. J Immunol 185(2):1222–1229
Metcalf D (2008) Hematopoietic cytokines. Blood 111(2):485–491
Motzer RJ, Ashok R, Thompson J et al (2002) Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 13:1799–1805
Ng EWM, Shima DT, Calias P et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132
Noelle RJ, Nowak EC (2010) Cellular source and immune functions of interleukin-9. Nat Rev Immunol 10:683–687
Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022
Pardo M, Castillo I, Oliva H et al (1997) A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 26(5):1318–1321
Pettit DK, Bonnert TP, Eisenman J et al (1997) Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem 272:2312–2318
Platanias L (2005) Mechanism of type I- and type II-interferon mediated signaling. Nat Rev Immunol 5:375–386
Pockros P, Patel K, O’Brien CB (2003) A multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C infection in patients with non-responsiveness to previous therapy. Hepatology 37:1368–1374
Pushparay PN, Tay HK, H’ng SC et al (2009) The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 106(24):9773–9778
Reddy KR, Modi WM, Pedder S (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 54:571–586
Remick DG (2005) Interleukin-8. Crit Care Med 33(Suppl):S466–S467
Ross RJM, Leung KC, Maamra M et al (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (Pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716–1723
Ryff JC (1996) Both cytokines and their antagonists have a place in clinical medicine. Eur Cytokine Netw 7:437 (Abstract 40)
Schellekens H (2006) Erythropoiesis-stimulating Agents ─ Present and Future. Business Briefing: European Endocrine Review 2006. Touch Briefings Publishers, London
Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
Steinman L (2007) A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13(2):139–145
Stumhofer JS, Laurence A, Wilson HW et al (2006) Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7:937–945
Talpaz M, Rakhit A, Rittweger K et al (2005) Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-a-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 11:6247–6455
Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE (2004) Interleukin (IL)-F6m IL-1F8, and IL-1F9 signal through IL-Rrp2 and IL-1RacP to activate the pathway leading to NF-κB and MAPKs. J Biol Chem 279:13677–13688
Towne JE, Blair R, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, John E, Sims JE (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem 286:42594–42602
Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity – review. Nat Rev Immunol 3:133–146
Trøseid M, Seljeflot I, Amesen H (2010) The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol 9:11–19
Tsunoda S, Ishikawa T, Watanabe M et al (2001) Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br J Haematol 112:181–188
von der Thüsen J, Kuiper J, van Berkel TJC, Biessen EAL (2003) Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 55:133–166
Wacker A, Linton D, Hitchen P et al (2002) N-linked glycosylation in campylobacter jejuni and its functional transfer into E. coli. Science 298:1790–1793
Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595–601
Wang M, Liang P (2005) Interleukin-24 and its receptors. Immunology 114:166–170
White UA, Stephens JM (2011) The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr Pharm Des 17(4):340–346
Wills RJ (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19:390–399
Wills-Karp M (2004) Interleukin-13 in asthma pathogenesis. Immunol Rev 202:175–190
Wisniewski JA, Borish L (2011) Novel cytokines and cytokine-producing T cells in allergic disorders. Allergy Asthma Proc 32(2):83–94
Xu W (2004) Interleukin-20. Int Immunopharmacol 4:527–633
Yamamoto Y, Tsutsumi Y, Yoshioka Y et al (2003) Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 21:546–552
Yi JS, Cox MA, Zajac AJ (2010) Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect 12(14–15):1111–1119
Zeuzem S, Hopf U, Carreno V et al (1999) A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 29:1280–1286
Zeuzem S, Welsch C, Herrmann E (2003) Pharmacokinetics of peginterferons. Semin Liver Dis 23(Suppl 1):23–28
Further Reading
Reviews which summarize the referenced subject in more detail:
Interferons
Meager A (ed) (2006) The interferons: characterization and application. WILEY-VCH, Weinheim. ISBN 9783527311804 Online ISBN: 3-527-31180-7
Pestka S, Krause CD, Walter M (2004a) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32
Pestka S (1981a) Interferons. In: Pestka S (ed) Methods in enzymology, vol 78. Academic Press, New York, p 632
Pestka S (1981b) Interferons. In: Pestka S (ed) Methods in enzymology, vol 79. Academic Press, New York, p 677
Pestka S (1986) Interferons. In: Pestka S (ed) Methods in enzymology, vol 119. Academic Press, New York, p 845
Special issue: the neoclassical pathways of interferon signaling (2005) J Interferon Cytokine Res. 25:731–811
Interleukins
Pestka S, Krause CD, Sarkar C et al (2004b) IL-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979
Sigal LH (2004a) Interleukins of current clinical relevance (part I). J Clin Rheumatol 10:353–359
Sigal LH (2004b) Interleukins of current clinical relevance (part II). J Clin Rheumatol 11:34–39
PEGylation
Bailon P, Palleroni A, Schaffer CA et al (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol. Conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem 12:195–202
Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459–476
Wang Y-S, Youngster S, Grace M et al (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547–570
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ryff, JC., Pestka, S. (2013). Interferons and Interleukins. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6486-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6486-0_21
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6485-3
Online ISBN: 978-1-4614-6486-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)